Pathogenesis, diagnosis and treatment of immune checkpoint inhibitor related bullous pemphigoid
As a new type of anti-tumor therapy, immune checkpoint inhibitor (ICI) can effectively improve the survival rate of tumor patients, but also bring a series of adverse reactions. Among these, immune-related cutaneous adverse events are prevalent. There is a relatively low incidence of bullous pemphig...
Saved in:
| Main Authors: | Yi SUN, Ji YANG |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shanghai Chinese Clinical Medicine Press Co., Ltd.
2025-04-01
|
| Series: | Zhongguo Linchuang Yixue |
| Subjects: | |
| Online Access: | https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20241038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Treatment of Immune Checkpoint Inhibitor–Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature
by: Chen J, et al.
Published: (2024-12-01) -
Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
by: Nika Kotnik, MD, et al.
Published: (2025-07-01) -
Bullous pemphigoid after Split Skin grafting in vitiligo patient
by: Siddharth Bhatt, et al.
Published: (2024-12-01) -
Bullous pemphigoid and morphea: Coexistence or an incidental association
by: Seema Rani, et al.
Published: (2024-12-01) -
Recent advances in the genetics and innate immune cells of bullous pemphigoid
by: Xiaoli Yang, et al.
Published: (2025-06-01)